Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.53 |
| ▸ | DRD4 | P21917 | 3/20 | 0.53 |
| ▸ | DRD1 | P21728 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | HRH1 | P35367 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6444622 | 0.89 | DRD2 (0.43) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL6465487 | 0.89 | DRD2 (0.50) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL7409000 | 0.82 | HRH4 (0.74) | DRD2HRH4DRD4DRD1MAPK1 | |
| SCHEMBL7835099 | 0.81 | DRD2 (0.60) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL11636450 | 0.79 | DRD2 (0.59) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL14962344 | 0.78 | DRD2 (0.50) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL7414566 | 0.76 | DRD2 (0.61) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL7406099 | 0.76 | HRH4 (0.70) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL6995661 | 0.75 | DRD2 (0.44) | DRD2HRH4DRD4DRD1LMNA | |
| SCHEMBL3696235 | 0.74 | DRD2 (0.60) | DRD2HRH4DRD4DRD1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050153954-A1 | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof | DR. REDDY'S LABORATORIES, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20050153954-A1 | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof | DR. REDDY'S LABORATORIES, INC. | 2005-07-14 | — | — | US | disclosed |
| WO-2003091260-A9 | NOVEL CRYSTALLINE POLYMORPH FORM-VI OF OLANZAPINE AND A PROCESS FOR PREPARATION THEREOF | REDDYS LAB LTD DR (IN) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003091260-A1 | NOVEL CRYSTALLINE POLYMORPH FORM-VI OF OLANZAPINE AND A PROCESS FOR PREPARATION THEREOF | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-11-06 | — | — | WO | disclosed |
| EP-0783890-A1 | Use of 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine for the treatment of fungal dermatitis | ELI LILLY AND COMPANY (US) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050153954-A1 | Novel crystalline polymorph form-vi of olanzapine and a process for preparation thereof | HTR3B, HTR1B, CYP4B1 | DRD2 48/4885HRH4 1188/4885DRD4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.